GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Other Income (Expense)

VALN (Valneva SE) Other Income (Expense) : $109.8 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Valneva SE Other Income (Expense)?

Valneva SE's other income expense for the Valneva SE's pretax income for the three months ended in Sep. 2024 was $4.4 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2024 was $109.8 Mil.


Valneva SE Other Income (Expense) Historical Data

The historical data trend for Valneva SE's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Other Income (Expense) Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.64 0.53 9.13 -13.40 6.11

Valneva SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.35 7.68 96.00 1.76 4.35

Valneva SE Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $109.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valneva SE  (NAS:VALN) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Valneva SE Business Description

Traded in Other Exchanges
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Valneva SE Headlines

From GuruFocus

Half Year 2021 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024

Full Year 2020 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024

Valneva SE - Special Call Transcript

By GuruFocus Research 02-09-2024

Valneva SE Corporate Analyst Meeting Transcript

By GuruFocus Research 02-09-2024

Q1 2023 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024

Valneva SE at Jefferies Healthcare Conference Transcript

By GuruFocus Research 02-09-2024

Valneva SE at Jefferies Healthcare Conference Transcript

By GuruFocus Research 02-09-2024